Expert Interview
Looking at Cardiff Oncology's Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC)
Ticker(s): CRDFInstitution: Duke University
- Gastrointestinal Oncologist and Professor of Medicine in the Department of Surgery at Duke University
- Manages 30+ patients with pancreatic cancer
- Research interest in immune therapies for treating GI cancers
Roughly how many patients with colorectal cancer do you manage?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for onvansertib?
Added By: ben_adminHow do you interpret the P2 data of onvansertib?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
